These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1412 related articles for article (PubMed ID: 27516446)

  • 41. Prognostic value of a three-scale grading system based on combining molecular imaging with
    Karfis I; Marin G; Levillain H; Drisis S; Muteganya R; Critchi G; Taraji-Schiltz L; Guix CA; Shaza L; Elbachiri M; Mans L; Machiels G; Hendlisz A; Flamen P
    Oncotarget; 2020 Feb; 11(6):589-599. PubMed ID: 32110279
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma.
    Conry BG; Papathanasiou ND; Prakash V; Kayani I; Caplin M; Mahmood S; Bomanji JB
    Eur J Nucl Med Mol Imaging; 2010 Jan; 37(1):49-57. PubMed ID: 19662413
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical utility of 2-[(18)F] fluoro-2-deoxy-D-glucose positron emission tomography in predicting World Health Organization grade in pancreatic neuroendocrine tumors.
    Tomimaru Y; Eguchi H; Tatsumi M; Kim T; Hama N; Wada H; Kawamoto K; Kobayashi S; Morii E; Mori M; Doki Y; Nagano H
    Surgery; 2015 Feb; 157(2):269-76. PubMed ID: 25311263
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Detection of Bone Metastases by
    Tian R; Xie Q; Yu F; Du C; Yao X; Zang S; Zhang C; Zhang P; Shao G; Yang Z; Wang F; Yu J
    Contrast Media Mol Imaging; 2022; 2022():1750132. PubMed ID: 36447752
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors.
    Deppen SA; Liu E; Blume JD; Clanton J; Shi C; Jones-Jackson LB; Lakhani V; Baum RP; Berlin J; Smith GT; Graham M; Sandler MP; Delbeke D; Walker RC
    J Nucl Med; 2016 May; 57(5):708-14. PubMed ID: 26769865
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
    Parghane RV; Talole S; Prabhash K; Basu S
    Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of
    Yu HN; Liu L; Chen QS; He Q; Li YS; Wang Y; Gao S
    Orthop Surg; 2021 May; 13(3):791-798. PubMed ID: 33709632
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of the application of 18F-FDG and 68Ga-DOTATATE PET/CT in neuroendocrine tumors: A retrospective study.
    Hu X; Li D; Wang R; Wang P; Cai J
    Medicine (Baltimore); 2023 May; 102(19):e33726. PubMed ID: 37171344
    [TBL] [Abstract][Full Text] [Related]  

  • 49.
    Lee H; Eads JR; Pryma DA
    Oncologist; 2021 Jan; 26(1):21-29. PubMed ID: 32886441
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
    Jois B; Asopa R; Basu S
    Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
    Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
    J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quantitative
    Ortega C; Wong RKS; Schaefferkoetter J; Veit-Haibach P; Myrehaug S; Juergens R; Laidley D; Anconina R; Liu A; Metser U
    J Nucl Med; 2021 Oct; 62(10):1406-1414. PubMed ID: 33579805
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Head-to-Head Comparison of
    Zhu W; Cheng Y; Wang X; Yao S; Bai C; Zhao H; Jia R; Xu J; Huo L
    J Nucl Med; 2020 Jun; 61(6):897-903. PubMed ID: 31676731
    [No Abstract]   [Full Text] [Related]  

  • 54. Comparison of ⁶⁸Ga-DOTATATE PET-CT, ¹⁸F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma.
    Ozkan ZG; Kuyumcu S; Uzum AK; Gecer MF; Ozel S; Aral F; Adalet I
    Nucl Med Commun; 2015 Mar; 36(3):242-50. PubMed ID: 25369749
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1).
    Lastoria S; Marciello F; Faggiano A; Aloj L; Caracò C; Aurilio M; D'Ambrosio L; Di Gennaro F; Ramundo V; Camera L; De Luca L; Fonti R; Napolitano V; Colao A
    Endocrine; 2016 Jun; 52(3):488-94. PubMed ID: 26242621
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PET/MRI in the Diagnosis of Hormone-Producing Pituitary Microadenoma: A Prospective Pilot Study.
    Wang H; Hou B; Lu L; Feng M; Zang J; Yao S; Feng F; Wang R; Li F; Zhu Z
    J Nucl Med; 2018 Mar; 59(3):523-528. PubMed ID: 28775202
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of
    Şahin OE; Uslu-Beşli L; Asa S; Sağer S; Sönmezoğlu K
    Hell J Nucl Med; 2020; 23(3):321-329. PubMed ID: 33367304
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Correlation of 68Ga-DOTATATE uptake on PET/CT with pathologic features of cellular proliferation in neuroendocrine neoplasms.
    Karls S; Gold R; Kravets S; Wang Y; Cheng S; Perez K; Chan J; Jacene H
    Ann Nucl Med; 2021 Sep; 35(9):1066-1077. PubMed ID: 34146243
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of peptide receptor radionuclide therapy (PRRT) with tandem isotopes - [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on [18F]FDG PET/CT qualification in Polish multicentre experience - do we need [18F]FDG PET/CT for qualification to PRRT?
    Zemczak A; Kołodziej M; Gut P; Królicki L; Kos-Kudła B; Kamiński G; Ruchała M; Pawlak D; Kunikowska J
    Endokrynol Pol; 2020; 71(3):240-248. PubMed ID: 32293704
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic Utility of Total
    Tirosh A; Papadakis GZ; Millo C; Hammoud D; Sadowski SM; Herscovitch P; Pacak K; Marx SJ; Yang L; Nockel P; Shell J; Green P; Keutgen XM; Patel D; Nilubol N; Kebebew E
    Gastroenterology; 2018 Mar; 154(4):998-1008.e1. PubMed ID: 29155309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 71.